By comparing the clinical side effects of these two FXR ligands, vidofludimus appears to be a multi-target drug for IBD and NAFLD treatment, and the potential of DHODH inhibition in therapeutic effect and toxicity worth further exploration. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.